Published in J Am Soc Nephrol on February 01, 2017
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med (1992) 18.74
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med (1993) 18.15
STUDIES ON EXPERIMENTAL HYPERTENSION : I. THE PRODUCTION OF PERSISTENT ELEVATION OF SYSTOLIC BLOOD PRESSURE BY MEANS OF RENAL ISCHEMIA. J Exp Med (1934) 14.72
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med (2007) 7.69
Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med (2013) 7.29
Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest (2002) 6.27
Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med (1996) 5.46
Elevation of serum angiotensin-converting-enzyme (ACE) level in sarcoidosis. Am J Med (1975) 5.41
Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature (2013) 4.57
Blood pressure control--special role of the kidneys and body fluids. Science (1991) 4.48
Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A (2006) 4.10
Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc (2012) 3.60
Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci U S A (1995) 3.54
Requirement of prorenin receptor and vacuolar H+-ATPase-mediated acidification for Wnt signaling. Science (2010) 3.04
AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension. Hypertension (2004) 2.86
Systematic review: Sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther (2014) 2.81
Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol (2002) 2.50
Olmesartan-associated enteropathy: results of a national survey. Aliment Pharmacol Ther (2014) 2.42
Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood (2008) 2.36
Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertension-induced renal damage. Circ Res (2007) 2.25
Intratubular renin-angiotensin system in hypertension. Hypertension (2011) 2.14
Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol (2003) 1.99
Regulation of T-cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol (2008) 1.98
A role for angiotensin II type 1 receptors on bone marrow-derived cells in the pathogenesis of angiotensin II-dependent hypertension. Hypertension (2009) 1.94
Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol (2006) 1.91
Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension (1998) 1.90
Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions. Am J Physiol Renal Physiol (2006) 1.83
Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest (1999) 1.80
A novel role for type 1 angiotensin receptors on T lymphocytes to limit target organ damage in hypertension. Circ Res (2012) 1.79
Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest (2010) 1.78
Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am J Physiol Regul Integr Comp Physiol (2010) 1.76
Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem (2004) 1.74
Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int (2000) 1.74
Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation (2008) 1.72
Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest (2008) 1.70
Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl (2002) 1.65
Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation (2004) 1.59
ACEI and ARB combination therapy in patients with macroalbuminuric diabetic nephropathy and low socioeconomic level: a double-blind randomized clinical trial. Clin Nephrol (2011) 1.58
Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension (2010) 1.50
Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component. Circ Res (2004) 1.49
Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension (2008) 1.48
Interleukin-1 Receptor Activation Potentiates Salt Reabsorption in Angiotensin II-Induced Hypertension via the NKCC2 Co-transporter in the Nephron. Cell Metab (2015) 1.47
Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J Clin Invest (2002) 1.45
Competing Actions of Type 1 Angiotensin II Receptors Expressed on T Lymphocytes and Kidney Epithelium during Cisplatin-Induced AKI. J Am Soc Nephrol (2016) 1.45
Vascular Type 1A Angiotensin II Receptors Control BP by Regulating Renal Blood Flow and Urinary Sodium Excretion. J Am Soc Nephrol (2015) 1.43
Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol (1998) 1.41
Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J Clin Invest (2009) 1.41
Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest (1993) 1.40
Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension (2003) 1.40
Angiotensin II sustains brain inflammation in mice via TGF-beta. J Clin Invest (2010) 1.39
Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol (2007) 1.31
Regulation of sodium balance and blood pressure by the AT(1A) receptor for angiotensin II. Hypertension (2000) 1.26
(Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes (2009) 1.24
Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice. J Clin Invest (1999) 1.21
Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke (2003) 1.19
Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney. J Am Soc Nephrol (1999) 1.18
Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats. Pharmacol Res (2008) 1.14
Actions of angiotensin II on the renal microvasculature. J Am Soc Nephrol (1999) 1.14
Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis. J Immunol (2010) 1.14
Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity. Am J Physiol Renal Physiol (2011) 1.13
Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol (2004) 1.12
Angiotensin-(1-7) and the g protein-coupled receptor MAS are key players in renal inflammation. PLoS One (2009) 1.12
Renal cortical vasoconstriction contributes to development of salt-sensitive hypertension after angiotensin II exposure. J Am Soc Nephrol (2001) 1.11
Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ Res (2010) 1.10
Identification of noncytotoxic and IL-10-producing CD8+AT2R+ T cell population in response to ischemic heart injury. J Immunol (2010) 1.08
Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. Am J Physiol Renal Physiol (2009) 1.07
Proximal tubule angiotensin AT2 receptors mediate an anti-inflammatory response via interleukin-10: role in renoprotection in obese rats. Hypertension (2013) 1.05
The carboxypeptidase ACE shapes the MHC class I peptide repertoire. Nat Immunol (2011) 1.04
Direct pro-inflammatory effects of prorenin on microglia. PLoS One (2014) 1.04
Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res (2009) 1.04
Loss of angiotensin-converting enzyme 2 enhances TGF-β/Smad-mediated renal fibrosis and NF-κB-driven renal inflammation in a mouse model of obstructive nephropathy. Lab Invest (2012) 1.02
Role of the angiotensin II AT2 receptor in inflammation and oxidative stress: opposing effects in lean and obese Zucker rats. Am J Physiol Renal Physiol (2011) 1.01
Tumor necrosis factor-α produced in the kidney contributes to angiotensin II-dependent hypertension. Hypertension (2014) 0.99
Renin-angiotensin system blockade is renoprotective in immune complex-mediated glomerulonephritis. J Am Soc Nephrol (2008) 0.97
Angiotensin inhibition reduces glomerular damage and renal chemokine expression in MRL/lpr mice. J Pharmacol Exp Ther (2003) 0.97
Effect of SQ 14225, an inhibitor of angiotensin I-converting enzyme, on the granulomatous response to Schistosoma mansoni eggs in mice. J Clin Invest (1981) 0.96
Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension. Hypertens Res (2010) 0.95
Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release. Heart (2002) 0.94
Deterioration of atherosclerosis in mice lacking angiotensin II type 1A receptor in bone marrow-derived cells. Lab Invest (2008) 0.93
Type 1 angiotensin receptors on macrophages ameliorate IL-1 receptor-mediated kidney fibrosis. J Clin Invest (2014) 0.92
The angiotensin II type 2 receptor and the kidney. J Renin Angiotensin Aldosterone Syst (2009) 0.92
The CD4(+) AT2R(+) T cell subpopulation improves post-infarction remodelling and restores cardiac function. J Cell Mol Med (2015) 0.90
Essential role of angiotensin II type 1a receptors in the host vascular wall, but not the bone marrow, in the pathogenesis of angiotensin II-induced atherosclerosis. Hypertens Res (2008) 0.90
Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. J Am Soc Nephrol (2011) 0.90
Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. Am J Physiol Renal Physiol (2002) 0.89
piggyBac-ing models and new therapeutic strategies. Trends Biotechnol (2015) 0.89
Association of an insertion polymorphism of angiotensin-converting enzyme gene with the activity of systemic lupus erythematosus. Lupus (1998) 0.89
Activation of Human T Cells in Hypertension: Studies of Humanized Mice and Hypertensive Humans. Hypertension (2016) 0.89
Linkage analysis of angiotensin-converting enzyme (ACE) insertion/deletion polymorphism and systemic lupus erythematosus. Mol Cell Endocrinol (2001) 0.88
Infliximab, a TNF-α inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patients. J Hum Hypertens (2013) 0.87
The role of urinary TGF-β₁, TNF-α, IL-6 and microalbuminuria for monitoring therapy in posterior urethral valves. Pediatr Nephrol (2013) 0.86
Changes in urinary albumin excretion, inflammatory and oxidative stress markers in ADPKD patients with hypertension. Am J Med Sci (2012) 0.85
Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int (1996) 0.85
Angiotensin-converting enzyme gene polymorphism in patients with systemic lupus. Acta Med Croatica (2001) 0.84
An essential role of angiotensin II receptor type 1a in recipient kidney, not in transplanted peripheral blood leukocytes, in progressive immune-mediated renal injury. Lab Invest (2001) 0.82